Myelin basic protein-like material in the urine of multiple sclerosis patients: Relationships to clinical and neuroimaging changes

Multiple Sclerosis

Volumn 4, Issue 3, 1998, Pages 243-246

  Whitaker, John N ^a,b  

^a The University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Magnetic resonance imaging; Multiple sclerosis; Myelin basic protein; Radioimmunoassay; Urine

Indexed keywords

BETA1 INTERFERON; EPITOPE; GLATIRAMER; MYELIN BASIC PROTEIN; PEPTIDE;

ARTICLE; BODY FLUID; CEREBROSPINAL FLUID; CHEMICAL ANALYSIS; CRYPT CELL; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOIMMUNOASSAY; SYSTEMIC SCLEROSIS; URINE; URINE LEVEL;

EID: 0031706533     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859800400329     Document Type: Article

References (51)

1. Lublin FD, Reingold SC. (1996) Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 46: 907 - 911.
2. The IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655 - 661.
3. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized. double-blind, placebo-controlled trial. Neurology 43: 662 - 667.
4. Jacobs LD et al. (1996) Intramuscular Interferon beta-1 alpha for disease progression in relapsing multiple sclerosis. Ann Neurol 39: 285 - 294.
5. Johnson KP et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45: 1268 - 1276.
6. Noseworthy JH, O'Brien PC, Mayo Clinic-Canadian Cooperative MS Study Group. (1997) The Mayo Clinic-Canadian Cooperative study of sulfasalazine (Salazopyrin EN) in active multiple sclerosis: preliminary report. Neurology 48: A340.
7. Weiner HL et al. (1993) Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259: 1321 - 1324.
8. Andersen O et al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47: 895 - 900.
9. Karussis DM et al. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 47: 341 - 346.
10. Whitaker JN, McFarland HF, Rudge P, Reingold SC. (1995) Outcomes assessment in multiple sclerosis clinical trials: A critical analysis Multiple Sclerosis 1: 37 - 47.
11. Bedell BJ, Narayana PA, Wolinsky JS. (1997) A dual approach for minimizing false lesion classifications on magnetic resonance images. MRM 37: 94 - 102.
12. Rudick R et al. (1997) Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 42: 379 - 382.
13. Whitaker JN, Snyder DS. (1982) Myelin components in the cerebrospinal fluid in diseases affecting central nervous system myelin. Clin Immunol Allergy 2: 469 - 482.
14. Whitaker JN. (1998) Myelin basic protein in cerebrospinal fluid and other body fluids. Mult Scl 4: 16 - 21.
15. Cuzner ML, Norton WT. (1996) Biochemistry of demyelination. Brain Pathol 6: 231 - 242.
16. Morell P, Quarles RH, Norton WT. (1989) Formation, structure and biochemistry of myelin. In: Siegel G, Agranoff B, Albers RW, Molinoff P, (eds). Basic neurochemistry Raven Press: New York 109 - 136.
17. Roach A et al. (1983) Characterization of cloned cDNA representing rat myelin basic protein: absence of expression in brain in shiverer mutant mice. Cell 42: 799 - 806.
18. Campagnoni AT. (1988) Molecular biology of myelin proteins from the central nervous system. J Neurochem 51: 1 - 14.
19. Kamholz J, deFerra F, Puckett C, Lazzarini RA. (1986) Identification of three forms of human myelin basic protein by cDNA cloning. Proc Natl Acad Sci USA 83: 4962 - 4966.
20. Moscarello MA. (1990) Myelin basic protein: A dynamically changing structure. In: Hashim GA, Moscarello M, (eds.) Dynamic Interactions of Myelin Proteins John Wiley: New York 25 - 48.
21. Hashim GA, Eylar EH. (1969) The structure of the terminal regions of the encephalitogenic basic protein from bovine myelin. Arch Biochem Biophys 135: 324 - 333.
22. Ramwani JJ, Epand RM, Moscarello MA. (1989) Secondary structure of charge isomers of myelin basic protein before and after phosphorylation. Biochemistry 28: 6538 - 6543.
23. Chou FC-H, Chou C-HJ, Shapira R, Kibler RF. (1976) Basis of microheterogeneity of myelin basic protein. J Biol Chem 251: 2671 - 2679.
24. Deibler GE, Martenson RE. (1973) Chromatographic fractionation of myelin basic protein. Partial characterization and methylarginine contents of multiple forms. J Biol Chem 248: 2392 - 2396.
25. Deibler GE et al. (1975) The contribution of phosphorylation and loss of COOH-terminal arginine to the microheterogeneity of myelin basic protein. J Biol Chem 250: 7931 - 7938.
26. Baldwin GS, Carnegie PM. (1971) Isolation and partial characterization of methylated arginines from the encephalitogenic basic protein of myelin. Biochem J 123: 69 - 74.
27. Wood DD, Moscarello MA. (1989) The isolation, characterization, and lipid-aggregating properties of a citrulline containing myelin basic protein. J Biol Chem 264: 5121 - 5127.
28. Fannon AM, Moscarello MA. (1990) Myelin basic protein is affected by reduced synthesis of myelin proteolipid protein in the jimpy mouse. Biochem J 268: 105 - 110.
29. Whitaker JN et al. (1992) An immunochemical comparison of human myelin basic protein and its modified, citrullinated form, C8. J Neuroimmunol 36: 135 - 146.
30. Martin R et al. (1991) T-cell recognition of a citrulline-containing myelin basic protein. Neurology 41: 257 - 258.
31. Whitaker JN, Chou CHJ, Chou FCH, Kibler RF. (1979) Antigenic regions for the humoral response to myelin basic protein. Mol Immunol 16: 495 - 501.
32. Day ED, Potter NT. (1986) Monoclonal and polyclonal antibodies to myelin basic protein determinants. J Neuroimmunol 10: 289 - 312.
33. Fallis RJ, Raine CS, McFarlin DE. (1989) Chronic relapsing experimental allergic encephalomyelitis in SJL mice following the adoptive transfer of an epitope-specific T cell line. J Neuroimmunol 22: 93 - 105.
34. Sakai K et al. (1988) Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein. J Neuroimmunol 19: 21 - 32.
35. Offner H et al. (1989) T cell determinants of myelin basic protein include a unique encephalitogenic I-E-restricted epitope for Lewis rats. J Exp Med 170: 355 - 367.
36. Warren KG, Catz I, Steinman L. (1995) Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: The minimal B-cell epitope and a model of its features. Proc Natl Acad Sci USA 92: 11061 - 11065.
37. Ota K et al. (1990) T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346: 183 - 187.
38. Bashir RM, Whitaker JN. (1980) Molecular features of immunoreactive myelin basic protein in cerebrospinal fluid of persons with multiple sclerosis. Ann Neurol 7: 50 - 57.
39. Gibson BW, Gilliom RD, Whitaker JN, Biemann K. (1984) Amino acid sequence of human myelin basic protein peptide 45-89 as determined by mass spectrometry. J Biol Chem 259: 5028 - 5031.
40. Whitaker JN et al. (1995) Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol 38: 625 - 632.
41. Stoner GL. (1984) Predicted folding of β-structure in myelin basic protein. J Neurochem 43: 433 - 447.
42. Zhou SR, Whitaker JN. (1990) An idiotype shared by monoclonal antibodies to different peptides of human myelin basic protein. J Immunol 145: 2554 - 2560.
43. Zhou S-R et al. (1998) A cross-reactive anti-myelin basic protein idiotope in cerebrospinal fluid cells in multiple sclerosis. Neurology 50: 411 - 417.
44. Whitaker JN, Bashir RM, Chou C-H, Kibler RF. (1980) Antigenic features of myelin basic protein-like material in cerebrospinal fluid. J Immunol 124: 1148 - 1153.
45. Percy AK, Goodwin J, Whitaker JN. (1996) Myelin basic protein-like material in urine: a developmental profile. Ann Neurol 40: 297.
46. Whitaker JN et al. (1994) Correlation of clinical features and findings on cranial magnetic resonance imaging with urinary myelin basic protein-like material in patients with multiple sclerosis. Ann Neurol 35: 577 - 585.
47. Whitaker JN, Chou CHJ, Chou FCH, Kibler RF. (1977) Molecular internalization of a region of myelin basic protein. J Exp Med 146: 317 - 331.
48. Whitaker JN. (1984) Indicators of disease activity in multiple sclerosis: Studies of myelin basic protein-like materials. Ann NY Acad Sci 436: 140 - 150.
49. Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33: 1444 - 1452.
50. Giovannoni G, Green A, Keir G, Thompson EJ. (1996) Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis - Letter to Editor. Ann Neurol 40: 128 - 129.
51. Whitaker JN. (1987) The presence of immunoreactive myelin basic protein peptide in urine of persons with multiple sclerosis. Ann Neurol 22: 648 - 655.